INmune Bio Q3 EPS $(0.60) Misses $(0.50) Estimate
Portfolio Pulse from Benzinga Newsdesk
INmune Bio reported a Q3 EPS loss of $(0.60), missing the analyst estimate of $(0.50) and showing a 25% increase in losses compared to the previous year.
October 31, 2024 | 8:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
INmune Bio's Q3 EPS of $(0.60) missed analyst expectations of $(0.50), marking a 25% increase in losses from the previous year.
The reported EPS loss of $(0.60) is worse than the expected $(0.50), indicating a negative surprise for investors. The increase in losses compared to the previous year suggests deteriorating financial performance, likely leading to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100